Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Omalizumab for Injection

Omalizumab is a humanized monoclonal antibody of human immunoglobulin E produced by Chinese hamster ovary cells using gene recombination technology. It can be used to treat allergic asthma and chronic spontaneous urticaria.
Allergic asthma: Omalizumab is suitable for the treatment of patients with confirmed (immunoglobulin E)-mediated asthma. It is suitable for adults, adolescents (12 years and above) and children (6 to 12 years old) for moderate to severe persistent allergic asthma whose symptoms cannot be effectively controlled after treatment with inhaled corticosteroids and long-acting inhaled β2-adrenergic receptor agonists. It can reduce the asthma exacerbation rate of these patients.
Chronic spontaneous urticaria: It is suitable for adults and adolescents (12 years and above) with chronic spontaneous urticaria who still have symptoms after treatment with H1 antihistamines.

Share:

Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.